TITLE

Adaptive immunity in cancer immunology and therapeutics

AUTHOR(S)
Spurrell, Emma L.; Lockley, Michelle
PUB. DATE
June 2014
SOURCE
Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The vast genetic alterations characteristic of tumours produce a number of tumour antigens that enable the immune system to differentiate tumour cells from normal cells. Counter to this, tumour cells have developed mechanisms by which to evade host immunity in their constant quest for growth and survival. Tumour-associated antigens (TAAs) are one of the fundamental triggers of the immune response. They are important because they activate, via major histocompatibility complex (MHC), the T cell response, an important line of defense against tumourigenesis. However, the persistence of tumours despite host immunity implies that tumour cells develop immune avoidance. An example of this is the up-regulation of inhibitory immune checkpoint proteins, by tumours, which induces a form of self-tolerance. The majority of monoclonal antibodies in clinical practice have been developed to target tumour-specific antigens. More recently there has been research in the down-regulation of immune checkpoint proteins as a way of increasing anti-tumour immunity.
ACCESSION #
97255417

 

Related Articles

  • Recipients with In Utero Induction of Tolerance Upregulated MHC Class I in the Engrafted Donor Skin. Jeng-Chang Chen; Liang-Shiou Ou; Hsiu-Yueh Yu; Ming-Ling Kuo; Pei-Yeh Chang; Hsueh-Ling Chang // Disease Markers;2014, p1 

    The alterations in MHC class I expression play a crucial step in immune evasion of cancer or virus-infected cells. This study aimed to examine whether tolerized grafts modified MHC class I expression. FVB/N mice were rendered tolerant of C57BL/6 alloantigens by in utero transplantation of...

  • The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions. Garrido, Federico; Algarra, Ignacio; García-Lora, Angel M. // Cancer Immunology, Immunotherapy;Oct2010, Vol. 59 Issue 10, p1601 

    The discovery of tumor antigens recognized by T lymphocytes has stimulated the development of a variety of cancer treatment protocols aimed at enhancing antitumor-specific T cell responses and tumor rejection. However, immunotherapy-mediated regression of established tumors and clearly positive...

  • Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. Daudi, Sayeema; Eng, Kevin H.; Mhawech-Fauceglia, Paulette; Morrison, Carl; Miliotto, Anthony; Beck, Amy; Matsuzaki, Junko; Tsuji, Takemasa; Groman, Adrienne; Gnjatic, Sacha; Spagnoli, Guillo; Lele, Shashikant; Odunsi, Kunle // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    The MAGE cancer-testis antigens (CTA) are attractive candidates for immunotherapy. The aim of this study was to determine the frequency of expression, humoral immunity and prognostic significance of MAGE CTA in human epithelial ovarian cancer (EOC). mRNA or protein expression frequencies were...

  • Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing. Hanada, Ken-ichi; Yang, James C. // Journal of Molecular Medicine;Jun2005, Vol. 83 Issue 6, p420 

    In the past 15 years, the molecular identification of antigens that can mediate the killing of tumor cells by T cells has been vigorously pursued. Molecular identification of tumor-associated antigens not only provided the means to activate or monitor anti-tumor immunity, but also gave insights...

  • CD4 T cells in tumor immunity. Gerloni, Mara; Zanetti, Maurizio // Springer Seminars in Immunopathology;Jun2005, Vol. 27 Issue 1, p37 

    T cell immunity is the key to protective immune responses against tumors. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. In recent years the realization that CD4 T cells can also play a relevant role in...

  • Characterization of MHC Ligands for Peptide Based Tumor Vaccination. Klug, Felix; Miller, Matthias; Schmidt, Hans-Henning; Stevanović, Stefan // Current Pharmaceutical Design;10/1/2009, Vol. 15 Issue 28, p3221 

    Short peptides derived from cellular proteins may escape complete destruction during protein catabolism and finally serve as a showcase in the immune system. Exposed at the cell surface to scrutiny by T cells, MHC:peptide complexes mediate a highly specific and immediate information transfer...

  • Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/ neu by human dendritic cells. Baleeiro, Renato B; Rietscher, René; Diedrich, Andrea; Czaplewska, Justyna A; Lehr, Claus-Michael; Scherließ, Regina; Hanefeld, Andrea; Gottschaldt, Michael; Walden, Peter // OncoImmunology;Nov2015, Vol. 4 Issue 11, pN.PAG 

    Cross-presentation is the process by which professional antigen presenting cells (APCs) (B cells, dendritic cells (DCs) and macrophages) present endocytosed antigens (Ags) via MHC-I to CD8+T cells. This process is crucial for induction of adaptive immune responses against tumors and infected...

  • Bridging Innate and Adaptive Antitumor Immunity Targeting Glycans. Pashov, Anastas; Monzavi-Karbassi, Bejatolah; Raghava, Gajendra P. S.; Kieber-Emmons, Thomas // Journal of Biomedicine & Biotechnology;2010, p1 

    Effective immunotherapy for cancer depends on cellular responses to tumor antigens. The role of major histocompatibility complex (MHC) in T-cell recognition and T-cell receptor repertoire selection has become a central tenet in immunology. Structurally, this does not contradict earlier findings...

  • Immunization with a Peptide Containing MHC Class I and II Epitopes Derived from the Tumor Antigen SIM2 Induces an Effective CD4 and CD8 T-Cell Response. Kissick, Haydn T.; Sanda, Martin G.; Dunn, Laura K.; Arredouani, Mohamed S. // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Here, we sought to determine whether peptide vaccines designed harbor both class I as well as class II restricted antigenic motifs could concurrently induce CD4 and CD8 T cell activation against autologous tumor antigens. Based on our prior genome-wide interrogation of human prostate cancer...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics